Nuveen LLC Acquires Shares of 114,634 Harmony Biosciences Holdings, Inc. $HRMY

Nuveen LLC purchased a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 114,634 shares of the company’s stock, valued at approximately $3,805,000. Nuveen LLC owned 0.20% of Harmony Biosciences as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Deep Track Capital LP bought a new position in Harmony Biosciences during the fourth quarter valued at approximately $49,894,000. LSV Asset Management lifted its stake in Harmony Biosciences by 25.0% in the first quarter. LSV Asset Management now owns 1,194,961 shares of the company’s stock worth $39,661,000 after acquiring an additional 238,744 shares during the period. Allianz Asset Management GmbH lifted its position in Harmony Biosciences by 1,709.0% during the first quarter. Allianz Asset Management GmbH now owns 220,704 shares of the company’s stock valued at $7,325,000 after buying an additional 208,504 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Harmony Biosciences by 15.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company’s stock valued at $41,739,000 after acquiring an additional 160,490 shares in the last quarter. Finally, Algert Global LLC raised its position in shares of Harmony Biosciences by 153.9% in the 4th quarter. Algert Global LLC now owns 230,908 shares of the company’s stock worth $7,946,000 after purchasing an additional 139,967 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Stock Up 2.4%

Harmony Biosciences stock opened at $38.05 on Thursday. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of 12.27, a PEG ratio of 0.44 and a beta of 0.84. The stock has a 50 day moving average of $34.77 and a two-hundred day moving average of $33.67. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The business had revenue of $200.49 million for the quarter, compared to analysts’ expectations of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period last year, the company posted $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

HRMY has been the subject of a number of recent research reports. Oppenheimer began coverage on Harmony Biosciences in a research note on Monday, June 2nd. They set an “outperform” rating and a $61.00 price target for the company. Mizuho increased their price target on Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, May 15th. Wall Street Zen downgraded Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Cantor Fitzgerald raised Harmony Biosciences to a “strong-buy” rating in a report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $55.00 price objective (up from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Harmony Biosciences has an average rating of “Buy” and a consensus price target of $51.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.